IDT Developing PrimeTime™ SARS-CoV-2/Flu Test for Comprehensive Patient Testing

Emerging technologies

Home » Emerging technologies

Benchling Doubles Annual Recurring Revenue (ARR) for Fourth Straight Year Amid COVID-19 Pandemic

The leading life sciences R&D cloud added 150 customers, including biotech innovators Gilead Sciences, Sanofi, and UCB SAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ — With biotech seizing headlines amid the COVID...

Protera Strengthens Board with Appointment of Dr. Oswaldo da Costa e Silva as Non-Executive Director

Codexis Introduces Improved Enzymes to Further Enhance Tate & Lyle’s Stevia and Allulose Production

REDWOOD CITY, Calif. and HOFFMANN ESTATES, Ill., Jan. 13, 2021 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Tate & Lyle...

Berkeley Lights Launches Opto Plasma B Discovery 4.0 to Accelerate Therapeutic Antibody Discovery Against Difficult Targets

Editas Medicine Announces The FDA Has Cleared Initiation Of The EDIT-301 Clinical Trial

Protein design

Biomatter Designs raises €500k to develop AI for Generative Protein Design

Twist Bioscience to Expand Commercial Capabilities with Factory of the Future

LanzaTech and TeselaGen Biotechnology Sign New Multi-Year Deal to Advance Carbon Remediation via Biological Processes

Draper

Draper Signs Agreement with Kite to Accelerate Development of Cancer Immunotherapies

Ginkgo Bioworks Acquires Biotechnology Startup Novogy’s Microbial Engineering Platform

CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV

CATALOG Hires Key Scientists, Names Advisory Board to Advance DNA Computing and Storage

Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Deepcell Closes $20 Million Series A Round to Develop AI-Powered Capture of Cells for Precision Medicine

Twist Bioscience Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares